{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,18]],"date-time":"2026-09-18T05:23:17Z","timestamp":1789708997024,"version":"4.0.1"},"publisher-location":"Cham","reference-count":48,"publisher":"Springer Nature Switzerland","isbn-type":[{"value":"9783031849879","type":"print"},{"value":"9783031849886","type":"electronic"}],"license":[{"start":{"date-parts":[[2025,1,1]],"date-time":"2025-01-01T00:00:00Z","timestamp":1735689600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2025,1,1]],"date-time":"2025-01-01T00:00:00Z","timestamp":1735689600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2025]]},"DOI":"10.1007\/978-3-031-84988-6_9","type":"book-chapter","created":{"date-parts":[[2025,6,9]],"date-time":"2025-06-09T06:56:07Z","timestamp":1749452167000},"page":"167-175","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Myelofibrosis: Timing of Transplantation and Management of Splenomegaly"],"prefix":"10.1007","author":[{"given":"Nicolaus","family":"Kr\u00f6ger","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kristin","family":"Rathje","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nico","family":"Gagelmann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,6,10]]},"reference":[{"issue":"9","key":"9_CR1","doi-asserted-by":"publisher","first-page":"1223","DOI":"10.1038\/bmt.2016.98","volume":"51","author":"H Alchalby","year":"2016","unstructured":"Alchalby H, Yunus DR, Zabelina T, Ayuk F, Kroger N (2016) Incidence and risk factors of poor graft function after allogeneic stem cell transplantation for myelofibrosis. Bone Marrow Transplant 51(9):1223\u20131227. https:\/\/doi.org\/10.1038\/bmt.2016.98","journal-title":"Bone Marrow Transplant"},{"issue":"3","key":"9_CR2","doi-asserted-by":"publisher","first-page":"476","DOI":"10.3324\/haematol.2009.011429","volume":"95","author":"EP Alessandrino","year":"2010","unstructured":"Alessandrino EP, Della Porta MG, Bacigalupo A et al (2010) Prognostic impact of pre-transplantation transfusion history and secondary iron overload in patients with myelodysplastic syndrome undergoing allogeneic stem cell transplantation: a GITMO study. Haematologica 95(3):476\u2013484. https:\/\/doi.org\/10.3324\/haematol.2009.011429","journal-title":"Haematologica"},{"issue":"11","key":"9_CR3","doi-asserted-by":"publisher","first-page":"1200","DOI":"10.1182\/blood.2022015850","volume":"140","author":"DA Arber","year":"2022","unstructured":"Arber DA, Orazi A, Hasserjian RP et al (2022) International consensus classification of myeloid neoplasms and acute Leukemias: integrating morphologic, clinical, and genomic data. Blood 140(11):1200\u20131228. https:\/\/doi.org\/10.1182\/blood.2022015850","journal-title":"Blood"},{"issue":"4","key":"9_CR4","doi-asserted-by":"publisher","first-page":"459","DOI":"10.1038\/s41409-023-01913-9","volume":"58","author":"JR Bales","year":"2023","unstructured":"Bales JR, Kim HT, Portillo R et al (2023) Splenic irradiation prior to allogeneic hematopoietic cell transplantation for patients with myelofibrosis. Bone Marrow Transplant 58(4):459\u2013461. https:\/\/doi.org\/10.1038\/s41409-023-01913-9","journal-title":"Bone Marrow Transplant"},{"issue":"3","key":"9_CR5","doi-asserted-by":"publisher","first-page":"358","DOI":"10.1016\/j.bbmt.2009.10.025","volume":"16","author":"KK Ballen","year":"2010","unstructured":"Ballen KK, Shrestha S, Sobocinski KA et al (2010) Outcome of transplantation for myelofibrosis. Biol Blood Marrow Transplant 16(3):358\u2013367. https:\/\/doi.org\/10.1016\/j.bbmt.2009.10.025","journal-title":"Biol Blood Marrow Transplant"},{"issue":"4","key":"9_CR6","doi-asserted-by":"publisher","first-page":"189","DOI":"10.1016\/j.jtct.2022.01.018","volume":"28","author":"C Cipkar","year":"2022","unstructured":"Cipkar C, Kumar S, Thavorn K, Kekre N (2022) Optimal timing of allogeneic stem cell transplantation for primary myelofibrosis. Transplant Cell Ther 28(4):189\u2013194. https:\/\/doi.org\/10.1016\/j.jtct.2022.01.018","journal-title":"Transplant Cell Ther"},{"issue":"4","key":"9_CR7","doi-asserted-by":"publisher","first-page":"370","DOI":"10.1111\/ejh.13294","volume":"103","author":"G Daghia","year":"2019","unstructured":"Daghia G, Zabelina T, Zeck G et al (2019) Allogeneic stem cell transplantation for myelofibrosis patients aged >\/=65 years. Eur J Haematol 103(4):370\u2013378. https:\/\/doi.org\/10.1111\/ejh.13294","journal-title":"Eur J Haematol"},{"issue":"2","key":"9_CR8","doi-asserted-by":"publisher","first-page":"115 e1","DOI":"10.1016\/j.jtct.2021.11.003","volume":"28","author":"S Essmann","year":"2022","unstructured":"Essmann S, Dadkhah A, Janson D, Wolschke C, Ayuk F, Kroger NM, Langebrake C (2022) Iron chelation with deferasirox increases busulfan AUC during conditioning chemotherapy prior to allogeneic stem cell transplantation. Transplant Cell Ther 28(2):115 e1\u2013115 e5. https:\/\/doi.org\/10.1016\/j.jtct.2021.11.003","journal-title":"Transplant Cell Ther"},{"issue":"1","key":"9_CR9","doi-asserted-by":"publisher","first-page":"42 e1","DOI":"10.1016\/j.jtct.2022.10.002","volume":"29","author":"S Essmann","year":"2023","unstructured":"Essmann S, Heestermans M, Dadkhah A et al (2023) Iron chelation with Deferasirox suppresses the appearance of labile plasma iron during conditioning chemotherapy prior to allogeneic stem cell transplantation. Transplant Cell Ther 29(1):42 e1\u201342 e6. https:\/\/doi.org\/10.1016\/j.jtct.2022.10.002","journal-title":"Transplant Cell Ther"},{"issue":"20","key":"9_CR10","doi-asserted-by":"publisher","first-page":"2233","DOI":"10.1182\/blood-2018-12-890889","volume":"133","author":"N Gagelmann","year":"2019","unstructured":"Gagelmann N, Ditschkowski M, Bogdanov R et al (2019) Comprehensive clinical-molecular transplant scoring system for myelofibrosis undergoing stem cell transplantation. Blood 133(20):2233\u20132242. https:\/\/doi.org\/10.1182\/blood-2018-12-890889","journal-title":"Blood"},{"issue":"4","key":"9_CR11","doi-asserted-by":"publisher","first-page":"1222","DOI":"10.1182\/bloodadvances.2021006827","volume":"6","author":"N Gagelmann","year":"2022","unstructured":"Gagelmann N, Wolschke C, Salit RB et al (2022) Reduced intensity hematopoietic stem cell transplantation for accelerated-phase myelofibrosis. Blood Adv 6(4):1222\u20131231. https:\/\/doi.org\/10.1182\/bloodadvances.2021006827","journal-title":"Blood Adv"},{"issue":"23","key":"9_CR12","doi-asserted-by":"publisher","first-page":"2901","DOI":"10.1182\/blood.2023019630","volume":"141","author":"N Gagelmann","year":"2023","unstructured":"Gagelmann N, Badbaran A, Salit RB et al (2023) Impact of TP53 on outcome of patients with myelofibrosis undergoing hematopoietic stem cell transplantation. Blood 141(23):2901\u20132911. https:\/\/doi.org\/10.1182\/blood.2023019630","journal-title":"Blood"},{"issue":"10","key":"9_CR13","doi-asserted-by":"publisher","first-page":"1011 e1","DOI":"10.1016\/j.jtct.2024.07.026","volume":"30","author":"N Gagelmann","year":"2024","unstructured":"Gagelmann N, Schuh C, Zeiser R et al (2024a) Allogeneic hematopoietic cell transplantation for Myelofibrosis aged 70 years or older: A study from the German registry for stem cell transplantation. Transplant Cell Ther 30(10):1011 e1\u20131011 e13. https:\/\/doi.org\/10.1016\/j.jtct.2024.07.026","journal-title":"Transplant Cell Ther"},{"issue":"5","key":"9_CR14","doi-asserted-by":"publisher","first-page":"844","DOI":"10.1002\/ajh.27252","volume":"99","author":"N Gagelmann","year":"2024","unstructured":"Gagelmann N, Hobbs GS, Campodonico E et al (2024b) Splenic irradiation for myelofibrosis prior to hematopoietic cell transplantation: A global collaborative analysis. Am J Hematol 99(5):844\u2013853. https:\/\/doi.org\/10.1002\/ajh.27252","journal-title":"Am J Hematol"},{"issue":"4","key":"9_CR15","doi-asserted-by":"publisher","first-page":"392","DOI":"10.1200\/JCO.2010.32.2446","volume":"29","author":"N Gangat","year":"2011","unstructured":"Gangat N, Caramazza D, Vaidya R et al (2011) DIPSS plus: a refined dynamic international prognostic scoring system for primary myelofibrosis that incorporates prognostic information from karyotype, platelet count, and transfusion status. J Clin Oncol 29(4):392\u2013397. https:\/\/doi.org\/10.1200\/JCO.2010.32.2446","journal-title":"J Clin Oncol"},{"issue":"9","key":"9_CR16","doi-asserted-by":"publisher","first-page":"1965","DOI":"10.1182\/bloodadvances.2019001084","volume":"4","author":"K Gowin","year":"2020","unstructured":"Gowin K, Ballen K, Ahn KW et al (2020) Survival following allogeneic transplant in patients with myelofibrosis. Blood Adv 4(9):1965\u20131973. https:\/\/doi.org\/10.1182\/bloodadvances.2019001084","journal-title":"Blood Adv"},{"issue":"15","key":"9_CR17","doi-asserted-by":"publisher","first-page":"1416","DOI":"10.1056\/NEJMoa1716614","volume":"379","author":"J Grinfeld","year":"2018","unstructured":"Grinfeld J, Nangalia J, Baxter EJ et al (2018) Classification and personalized prognosis in myeloproliferative neoplasms. N Engl J Med 379(15):1416\u20131430. https:\/\/doi.org\/10.1056\/NEJMoa1716614","journal-title":"N Engl J Med"},{"issue":"4","key":"9_CR18","doi-asserted-by":"publisher","first-page":"310","DOI":"10.1200\/JCO.2017.76.4886","volume":"36","author":"P Guglielmelli","year":"2018","unstructured":"Guglielmelli P, Lasho TL, Rotunno G et al (2018) MIPSS70: mutation-enhanced international prognostic score system for transplantation-age patients with primary myelofibrosis. J Clin Oncol 36(4):310\u2013318. https:\/\/doi.org\/10.1200\/JCO.2017.76.4886","journal-title":"J Clin Oncol"},{"issue":"9","key":"9_CR19","doi-asserted-by":"publisher","first-page":"787","DOI":"10.1056\/NEJMoa1110556","volume":"366","author":"C Harrison","year":"2012","unstructured":"Harrison C, Kiladjian JJ, Al-Ali HK et al (2012) JAK inhibition with ruxolitinib versus best available therapy for myelofibrosis. N Engl J Med 366(9):787\u2013798. https:\/\/doi.org\/10.1056\/NEJMoa1110556","journal-title":"N Engl J Med"},{"issue":"2","key":"9_CR20","doi-asserted-by":"publisher","first-page":"16","DOI":"10.1007\/s12032-019-1245-5","volume":"36","author":"G Helbig","year":"2019","unstructured":"Helbig G, Wieczorkiewicz-Kabut A, Markiewicz M et al (2019) Splenic irradiation before allogeneic stem cell transplantation for myelofibrosis. Med Oncol 36(2):16. https:\/\/doi.org\/10.1007\/s12032-019-1245-5","journal-title":"Med Oncol"},{"issue":"1","key":"9_CR21","doi-asserted-by":"publisher","first-page":"215","DOI":"10.1038\/s41375-020-0815-z","volume":"35","author":"JC Hernandez-Boluda","year":"2021","unstructured":"Hernandez-Boluda JC, Pereira A, Kroger N et al (2021) Determinants of survival in myelofibrosis patients undergoing allogeneic hematopoietic cell transplantation. Leukemia 35(1):215\u2013224. https:\/\/doi.org\/10.1038\/s41375-020-0815-z","journal-title":"Leukemia"},{"issue":"5","key":"9_CR22","doi-asserted-by":"publisher","first-page":"371","DOI":"10.1016\/j.jtct.2020.11.007","volume":"27","author":"A Isidori","year":"2021","unstructured":"Isidori A, Loscocco F, Visani G et al (2021) Iron toxicity and chelation therapy in hematopoietic stem cell transplant. Transplant Cell Ther 27(5):371\u2013379. https:\/\/doi.org\/10.1016\/j.jtct.2020.11.007","journal-title":"Transplant Cell Ther"},{"issue":"5","key":"9_CR23","doi-asserted-by":"publisher","first-page":"259 e1","DOI":"10.1016\/j.jtct.2022.02.004","volume":"28","author":"T Jain","year":"2022","unstructured":"Jain T, Tsai HL, DeZern AE et al (2022) Post-transplantation cyclophosphamide-based graft- versus-host disease prophylaxis with nonmyeloablative conditioning for blood or marrow transplantation for myelofibrosis. Transplant Cell Ther 28(5):259 e1\u2013259 e11. https:\/\/doi.org\/10.1016\/j.jtct.2022.02.004","journal-title":"Transplant Cell Ther"},{"issue":"26","key":"9_CR24","doi-asserted-by":"publisher","first-page":"5264","DOI":"10.1182\/blood-2009-07-234880","volume":"114","author":"N Kroger","year":"2009","unstructured":"Kroger N, Holler E, Kobbe G et al (2009) Allogeneic stem cell transplantation after reduced-intensity conditioning in patients with myelofibrosis: a prospective, multicenter study of the Chronic Leukemia Working Party of the European Group for Blood and Marrow Transplantation. Blood 114(26):5264\u20135270. https:\/\/doi.org\/10.1182\/blood-2009-07-234880","journal-title":"Blood"},{"issue":"21","key":"9_CR25","doi-asserted-by":"publisher","first-page":"3347","DOI":"10.1182\/blood-2014-10-608315","volume":"125","author":"N Kroger","year":"2015","unstructured":"Kroger N, Giorgino T, Scott BL et al (2015) Impact of allogeneic stem cell transplantation on survival of patients less than 65 years of age with primary myelofibrosis. Blood 125(21):3347\u20133350.; quiz 3364. https:\/\/doi.org\/10.1182\/blood-2014-10-608315","journal-title":"Blood"},{"issue":"10","key":"9_CR26","doi-asserted-by":"publisher","first-page":"2152","DOI":"10.1016\/j.bbmt.2018.05.023","volume":"24","author":"N Kroger","year":"2018","unstructured":"Kroger N, Shahnaz Syed Abd Kadir S, Zabelina T, Badbaran A, Christopeit M, Ayuk F, Wolschke C (2018) Peritransplantation ruxolitinib prevents acute graft-versus-host disease in patients with myelofibrosis undergoing allogenic stem cell transplantation. Biol Blood Marrow Transplant 24(10):2152\u20132156. https:\/\/doi.org\/10.1016\/j.bbmt.2018.05.023","journal-title":"Biol Blood Marrow Transplant"},{"issue":"12","key":"9_CR27","doi-asserted-by":"publisher","first-page":"3551","DOI":"10.1038\/s41375-021-01276-4","volume":"35","author":"N Kroger","year":"2021","unstructured":"Kroger N, Sbianchi G, Sirait T et al (2021) Impact of prior JAK-inhibitor therapy with ruxolitinib on outcome after allogeneic hematopoietic stem cell transplantation for myelofibrosis: a study of the CMWP of EBMT. Leukemia 35(12):3551\u20133560. https:\/\/doi.org\/10.1038\/s41375-021-01276-4","journal-title":"Leukemia"},{"issue":"20","key":"9_CR28","doi-asserted-by":"publisher","first-page":"1683","DOI":"10.1182\/blood.2023021218","volume":"142","author":"N Kroger","year":"2023","unstructured":"Kroger N, Wolschke C, Gagelmann N (2023) How I treat transplant-eligible patients with myelofibrosis. Blood 142(20):1683\u20131696. https:\/\/doi.org\/10.1182\/blood.2023021218","journal-title":"Blood"},{"issue":"1","key":"9_CR29","doi-asserted-by":"publisher","first-page":"e62","DOI":"10.1016\/S2352-3026(23)00305-8","volume":"11","author":"N Kroger","year":"2024","unstructured":"Kroger N, Bacigalupo A, Barbui T et al (2024) Indication and management of allogeneic haematopoietic stem-cell transplantation in myelofibrosis: updated recommendations by the EBMT\/ELN International Working Group. Lancet Haematol 11(1):e62\u2013e74. https:\/\/doi.org\/10.1016\/S2352-3026(23)00305-8","journal-title":"Lancet Haematol"},{"issue":"3","key":"9_CR30","doi-asserted-by":"publisher","first-page":"856","DOI":"10.1038\/s41375-021-01449-1","volume":"36","author":"S Kunte","year":"2022","unstructured":"Kunte S, Rybicki L, Viswabandya A et al (2022) Allogeneic blood or marrow transplantation with haploidentical donor and post-transplantation cyclophosphamide in patients with myelofibrosis: a multicenter study. Leukemia 36(3):856\u2013864. https:\/\/doi.org\/10.1038\/s41375-021-01449-1","journal-title":"Leukemia"},{"issue":"7","key":"9_CR31","doi-asserted-by":"publisher","first-page":"755","DOI":"10.1038\/s41409-023-01968-8","volume":"58","author":"M Luther","year":"2023","unstructured":"Luther M, Henes FO, Zabelina T et al (2023) Spleen volume and length determined by computed tomography impact outcome after allogeneic stem cell transplantation for myelofibrosis. Bone Marrow Transplant 58(7):755\u2013761. https:\/\/doi.org\/10.1038\/s41409-023-01968-8","journal-title":"Bone Marrow Transplant"},{"issue":"6","key":"9_CR32","doi-asserted-by":"publisher","first-page":"1855","DOI":"10.1182\/bloodadvances.2021006889","volume":"6","author":"M Maffioli","year":"2022","unstructured":"Maffioli M, Mora B, Ball S et al (2022) A prognostic model to predict survival after 6 months of ruxolitinib in patients with myelofibrosis. Blood Adv 6(6):1855\u20131864. https:\/\/doi.org\/10.1182\/bloodadvances.2021006889","journal-title":"Blood Adv"},{"issue":"32","key":"9_CR33","doi-asserted-by":"publisher","first-page":"4993","DOI":"10.1200\/JCO.22.01972","volume":"41","author":"J Mascarenhas","year":"2023","unstructured":"Mascarenhas J, Kremyanskaya M, Patriarca A et al (2023) MANIFEST: Pelabresib in combination with ruxolitinib for Janus kinase inhibitor treatment-naive myelofibrosis. J Clin Oncol 41(32):4993\u20135004. https:\/\/doi.org\/10.1200\/JCO.22.01972","journal-title":"J Clin Oncol"},{"issue":"9","key":"9_CR34","doi-asserted-by":"publisher","first-page":"2160","DOI":"10.1038\/s41409-021-01305-x","volume":"56","author":"D McLornan","year":"2021","unstructured":"McLornan D, Eikema DJ, Czerw T et al (2021) Trends in allogeneic haematopoietic cell transplantation for myelofibrosis in Europe between 1995 and 2018: a CMWP of EBMT retrospective analysis. Bone Marrow Transplant 56(9):2160\u20132172. https:\/\/doi.org\/10.1038\/s41409-021-01305-x","journal-title":"Bone Marrow Transplant"},{"issue":"2","key":"9_CR35","doi-asserted-by":"publisher","first-page":"361","DOI":"10.1002\/cncr.22021","volume":"107","author":"RA Mesa","year":"2006","unstructured":"Mesa RA, Nagorney DS, Schwager S, Allred J, Tefferi A (2006) Palliative goals, patient selection, and perioperative platelet management: outcomes and lessons from 3 decades of splenectomy for myelofibrosis with myeloid metaplasia at the Mayo Clinic. Cancer 107(2):361\u2013370. https:\/\/doi.org\/10.1002\/cncr.22021","journal-title":"Cancer"},{"issue":"16","key":"9_CR36","doi-asserted-by":"publisher","first-page":"1954","DOI":"10.1182\/blood.2022017423","volume":"141","author":"F Passamonti","year":"2023","unstructured":"Passamonti F, Mora B (2023) Myelofibrosis. Blood 141(16):1954\u20131970. https:\/\/doi.org\/10.1182\/blood.2022017423","journal-title":"Blood"},{"issue":"9","key":"9_CR37","doi-asserted-by":"publisher","first-page":"1703","DOI":"10.1182\/blood-2009-09-245837","volume":"115","author":"F Passamonti","year":"2010","unstructured":"Passamonti F, Cervantes F, Vannucchi AM et al (2010) A dynamic prognostic model to predict survival in primary myelofibrosis: a study by the IWG-MRT (International Working Group for Myeloproliferative Neoplasms Research and Treatment). Blood 115(9):1703\u20131708. https:\/\/doi.org\/10.1182\/blood-2009-09-245837","journal-title":"Blood"},{"issue":"12","key":"9_CR38","doi-asserted-by":"publisher","first-page":"2726","DOI":"10.1038\/leu.2017.169","volume":"31","author":"F Passamonti","year":"2017","unstructured":"Passamonti F, Giorgino T, Mora B et al (2017) A clinical-molecular prognostic model to predict survival in patients with post polycythemia vera and post essential thrombocythemia myelofibrosis. Leukemia 31(12):2726\u20132731. https:\/\/doi.org\/10.1038\/leu.2017.169","journal-title":"Leukemia"},{"issue":"1","key":"9_CR39","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1002\/ajh.26020","volume":"96","author":"N Polverelli","year":"2021","unstructured":"Polverelli N, Mauff K, Kroger N et al (2021) Impact of spleen size and splenectomy on outcomes of allogeneic hematopoietic cell transplantation for myelofibrosis: A retrospective analysis by the chronic malignancies working party on behalf of European society for blood and marrow transplantation (EBMT). Am J Hematol 96(1):69\u201379. https:\/\/doi.org\/10.1002\/ajh.26020","journal-title":"Am J Hematol"},{"issue":"5","key":"9_CR40","doi-asserted-by":"publisher","first-page":"993","DOI":"10.1002\/ajh.27262","volume":"99","author":"N Polverelli","year":"2024","unstructured":"Polverelli N, Bonneville EF, de Wreede LC et al (2024) Impact of comorbidities and body mass index on the outcomes of allogeneic hematopoietic cell transplantation in myelofibrosis: a study on behalf of the chronic malignancies working party of EBMT. Am J Hematol 99(5):993\u2013996. https:\/\/doi.org\/10.1002\/ajh.27262","journal-title":"Am J Hematol"},{"issue":"6","key":"9_CR41","doi-asserted-by":"publisher","first-page":"721","DOI":"10.1111\/j.1365-2141.2010.08276.x","volume":"150","author":"M Robin","year":"2010","unstructured":"Robin M, Esperou H, de Latour RP, Petropoulou AD, Xhaard A, Ribaud P, Socie G (2010) Splenectomy after allogeneic haematopoietic stem cell transplantation in patients with primary myelofibrosis. Br J Haematol 150(6):721\u2013724. https:\/\/doi.org\/10.1111\/j.1365-2141.2010.08276.x","journal-title":"Br J Haematol"},{"issue":"6","key":"9_CR42","doi-asserted-by":"publisher","first-page":"958","DOI":"10.1016\/j.bbmt.2017.03.002","volume":"23","author":"M Robin","year":"2017","unstructured":"Robin M, Zine M, Chevret S et al (2017) The impact of splenectomy in myelofibrosis patients before allogeneic hematopoietic stem cell transplantation. Biol Blood Marrow Transplant 23(6):958\u2013964. https:\/\/doi.org\/10.1016\/j.bbmt.2017.03.002","journal-title":"Biol Blood Marrow Transplant"},{"issue":"3","key":"9_CR43","doi-asserted-by":"publisher","first-page":"678","DOI":"10.1038\/leu.2016.260","volume":"31","author":"DT Saenz","year":"2017","unstructured":"Saenz DT, Fiskus W, Manshouri T et al (2017) BET protein bromodomain inhibitor-based combinations are highly active against post-myeloproliferative neoplasm secondary AML cells. Leukemia 31(3):678\u2013687. https:\/\/doi.org\/10.1038\/leu.2016.260","journal-title":"Leukemia"},{"issue":"3","key":"9_CR44","doi-asserted-by":"publisher","first-page":"799","DOI":"10.1038\/s41375-019-0603-9","volume":"34","author":"FPS Santos","year":"2020","unstructured":"Santos FPS, Getta B, Masarova L et al (2020) Prognostic impact of RAS-pathway mutations in patients with myelofibrosis. Leukemia 34(3):799\u2013810. https:\/\/doi.org\/10.1038\/s41375-019-0603-9","journal-title":"Leukemia"},{"issue":"7","key":"9_CR45","doi-asserted-by":"publisher","first-page":"2226","DOI":"10.1182\/blood.V95.7.2226","volume":"95","author":"A Tefferi","year":"2000","unstructured":"Tefferi A, Mesa RA, Nagorney DM, Schroeder G, Silverstein MN (2000) Splenectomy in myelofibrosis with myeloid metaplasia: a single-institution experience with 223 patients. Blood 95(7):2226\u20132233. https:\/\/www.ncbi.nlm.nih.gov\/pubmed\/10733489","journal-title":"Blood"},{"issue":"10","key":"9_CR46","doi-asserted-by":"publisher","first-page":"2274","DOI":"10.1038\/s41375-018-0078-0","volume":"32","author":"A Tefferi","year":"2018","unstructured":"Tefferi A, Finke CM, Lasho TL, Hanson CA, Ketterling RP, Gangat N, Pardanani A (2018a) U2AF1 mutation types in primary myelofibrosis: phenotypic and prognostic distinctions. Leukemia 32(10):2274\u20132278. https:\/\/doi.org\/10.1038\/s41375-018-0078-0","journal-title":"Leukemia"},{"issue":"7","key":"9_CR47","doi-asserted-by":"publisher","first-page":"1631","DOI":"10.1038\/s41375-018-0107-z","volume":"32","author":"A Tefferi","year":"2018","unstructured":"Tefferi A, Guglielmelli P, Nicolosi M et al (2018b) GIPSS: genetically inspired prognostic scoring system for primary myelofibrosis. Leukemia 32(7):1631\u20131642. https:\/\/doi.org\/10.1038\/s41375-018-0107-z","journal-title":"Leukemia"},{"issue":"9","key":"9_CR48","doi-asserted-by":"publisher","first-page":"799","DOI":"10.1056\/NEJMoa1110557","volume":"366","author":"S Verstovsek","year":"2012","unstructured":"Verstovsek S, Mesa RA, Gotlib J et al (2012) A double-blind, placebo-controlled trial of ruxolitinib for myelofibrosis. N Engl J Med 366(9):799\u2013807. https:\/\/doi.org\/10.1056\/NEJMoa1110557","journal-title":"N Engl J Med"}],"container-title":["Advances in Experimental Medicine and Biology","Clinical Management of Challenges in Allogeneic Stem Cell Transplant"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/978-3-031-84988-6_9","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,6,9]],"date-time":"2025-06-09T06:56:08Z","timestamp":1749452168000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/978-3-031-84988-6_9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025]]},"ISBN":["9783031849879","9783031849886"],"references-count":48,"URL":"https:\/\/doi.org\/10.1007\/978-3-031-84988-6_9","relation":{},"ISSN":["0065-2598","2214-8019"],"issn-type":[{"value":"0065-2598","type":"print"},{"value":"2214-8019","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025]]},"assertion":[{"value":"10 June 2025","order":1,"name":"first_online","label":"First Online","group":{"name":"ChapterHistory","label":"Chapter History"}}]}}